Cure8 research brief
Distinguishing IBD from gastrointestinal tuberculosis is challenging in regions where GITB is common; histologic markers like basal plasmacytosis and eosinophilia on mucosal biopsy could help guide diagnosis when combined with other clinical information.
Clinicians (gastroenterologists, pathologists), researchers studying diagnostic biomarkers for IBD vs GITB, and patients in regions where GITB is a diagnostic consideration.
This retrospective study reviewed 412 eligible mucosal biopsies (UC, CD, GITB, and unclassified IBD) and found BP to be significantly more common in UC and CD than in GITB. Combining BP with mucosal eosinophilia (BP+ME) increased the diagnostic distinction between IBD and GITB.
Finding BP in three or more biopsy fragments strengthened the likelihood of IBD over GITB. Practical point The authors report moderate diagnostic utility (positive likelihood ratios in the range reported) — meaning these histologic features can support, but not definitively establish, a diagnosis of IBD versus GITB.
These markers should be interpreted alongside clinical, endoscopic, radiologic, and microbiological data.
This is a retrospective histopathology study reported as an abstract/summary in a peer-reviewed journal; results show moderate diagnostic value but do not replace comprehensive clinical assessment. The study population and regional prevalence of GITB may affect applicability to other settings.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Competing interests: None declared.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Patients and clinicians may care because the study suggests contrast-enhanced CT can reliably detect and localize IBD, including transmural and small-bowel disease that biopsies miss, which could affect diagnostic...
Endoscopy in this pediatric multicenter series found a high diagnostic yield and confirmed IBD and other treatable conditions; this matters for families and clinicians in resource-limited settings because improving...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
